Synairgen plc (SNG.L)
LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 04:28PM GMT
| Previous Close | 13.85 |
| Open | 13.50 |
| Bid | 12.50 x 0 |
| Ask | 16.40 x 0 |
| Day's Range | 13.20 - 15.00 |
| 52 Week Range | 10.00 - 209.80 |
| Volume | |
| Avg. Volume | 485,253 |
| Market Cap | 28.188M |
| Beta (5Y Monthly) | -2.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.10 |
| Earnings Date | Sept 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Companies Like Synairgen (LON:SNG) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Institutions profited after Synairgen plc's (LON:SNG) market cap rose UK£4.7m last week butindividual investors profited the most
Every investor in Synairgen plc ( LON:SNG ) should be aware of the most powerful shareholder groups. With 36% stake...
- Business Wire
Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19
SOUTHAMPTON, England, October 04, 2022--Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta to treat or prevent severe viral lung infections, today announces topline data for participants treated with SNG001 in the US National Institutes of Health (NIH)/ AIDS Clinical Trials Group (ACTG)-led ACTIV-2 Phase 2 adaptive platform trial for COVID-19.
© 2023 Yahoo. All rights reserved.
